Phlow Corp. – Trademark Portfolio
Entity Type: 03
Phlow Corp. owns a portfolio of 12 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), including well-known marks such as PHLOW, SAPIR, and APDC ADVANCED PHARMACEUTICAL DEVELOPMENT CENTER. Of these, 7 are registered and 1 is pending. The portfolio spans 7 Nice Classification classes, led by Class 40 (Treatment & Processing) and Class 42 (Computer & Scientific). Headquartered in Richmond, VA.
424 Hull St., Suite 400
Richmond, VA 23224
Showing of trademarks Trademarks
Trademark Classifications
Phlow Corp.'s trademark portfolio spans 7 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Scientific and technological services; industrial analysis and research services
Advertising; business management; business administration; office functions
Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes
Chemical products for industry, science, photography, agriculture, horticulture and forestry
Frequently Asked Questions
How many trademarks does Phlow Corp. have?
Phlow Corp. has 12 U.S. trademarks filed with the USPTO. Of these, 7 registered, 1 pending, 4 abandoned.
What trademark classes does Phlow Corp. file in?
Phlow Corp. files trademarks across 7 Nice Classification classes. The most active classes are Class 40 (Treatment & Processing), Class 42 (Computer & Scientific), Class 35 (Advertising & Business), Class 5 (Pharmaceuticals), Class 1 (Chemicals). Class 40 covers treatment of materials.
What are Phlow Corp.'s most well-known trademarks?
Phlow Corp.'s registered trademark portfolio includes well-known marks such as PHLOW, SAPIR, and APDC ADVANCED PHARMACEUTICAL DEVELOPMENT CENTER. These are among 7 currently registered trademarks in the portfolio.
What is Phlow Corp.'s trademark registration success rate?
Phlow Corp. has a 64% trademark registration rate, with 7 out of 11 resolved applications resulting in successful registration. Currently, 1 application is pending review.